Antidiabetic Agents

Linaglip is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Linaglip may be used as monotherapy or in combination with other common antidiabetic medications including Metformin, Sulfonylurea, Pioglitazone, or Insulin. As a replacement therapy it is suitable when Metformin therapy is not appropriate due to intolerance or do not provide adequate glycemic control as monotherapy or other antidiabetic drugs are to be discontinued due to renal or hepatic impairment.

Linaglip Tablet: Each film coated tablet contains Linagliptin INN 5 mg.

Linaglip Tablet: Each box contains 30`s tablets in alu-alu blister pack. (New Packaging)

The recommended dose of Linaglip is 5 mg once daily and can be taken with or without food. If added with Metformin, the dose of Metformin should be maintained and Linaglip administered concomitantly. When used in combination with Sulfonylurea, a lower dose of Sulfonylurea may be considered to reduce the risk of hypoglycemia. Should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis

Linaglip is contraindicated to patients hypersensitive to Linagliptin or any of the excipients.

Some of the less common side effects are nasopharyngitis, hypoglycemia.

Linagliptin doesn't interact with Metformin, Glyburide, Simvastatin, Warfarin, Digoxin or oral contraceptives. Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes. Again it doesn't act as an inducer of CYP isozymes.

Aristopharma Ltd., Bangladesh.